VetCell Therapeutics is currently in the clinical testing review phase for its allogenic products and has begun preparations for clinical trials in the US. These trials are projected to last for 4-6 years. All data will be used to support the investigational new animal drug (INAD) application for Center for Veterinary Medicine’s (CVM, part of FDA) review and approval.
|Therapy Type||Pipeline Status||Target Date|
|Allogenic MSC for Canine AD||Recruiting for pre-clinical study||2018/2019|
|Allogenic MSC for Canine OA||Initiated Clinical Study||2020|
|Allogenic MSC for Feline FCGS||Initiated Clinical Study||2020|
Copyright © 2017 PrimeGen Biotech, LLC
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images and information, contained on or available through this web site is for general information purposes only. VetCell Therapeutics makes no representation and assumes no responsibility for the accuracy of information contained on or available through this web site, and such information is subject to change without notice.
You are encouraged to confirm any information obtained from or through this web site with other sources, and review all information regarding any medical condition or treatment with your physician.
NEVER DISREGARD PROFESSIONAL MEDICAL ADVICE OR DELAY SEEKING MEDICAL TREATMENT BECAUSE OF SOMETHING YOU HAVE READ ON OR ACCESSED THROUGH ANY WEB SITE.